Followers | 74 |
Posts | 3739 |
Boards Moderated | 0 |
Alias Born | 03/23/2013 |

Friday, June 13, 2025 7:37:04 PM

Clearly, there is grave concern about the prospects for higher prices based on:
1. The inability to take out overhead resistance (purple highlight).
2. The anemic volume behind the recent rally (red arrow).
3. The pattern of sharp reversals on the heels of the 2nd green impulse candles. This pattern has been intact since the breakdown from the top.
4. The RSI remains well below the bullish level of 50 (pink highlight).
Looking at the right edge, prices stabbed up into resistance on the weakest volume over the past 4 monthly candles. This demonstrates the strength of the trend which is down. If prices were going blow up through this resistance, we would see expanding volume as overhead is approached. Instead, we see the opposite.
What do you think is in store for the next candle? Now you know why I keep asking if anyone out there is wise enough to sell into this dead-cat bounce. Now you know why I keep talking about resistance, volume, trend, and RSI strength. They are all extremely weak on the long term chart.
Everyone is giddy about riding this recent wave... not realizing that the tide is working against that wave.
FOMO makes you blood thirsty to the extent you can't stop licking a knife edge covered with frozen blood.
Recent AMRN News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/01/2025 01:30:04 AM
- Amarin Stock Surges 11% After $25 Million Licensing Deal with Recordati • IH Market News • 06/24/2025 02:09:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/24/2025 11:05:28 AM
- Amarin Announces Exclusive License and Supply Agreement with Recordati to Commercialize VAZKEPA® (Icosapent Ethyl) in Europe • GlobeNewswire Inc. • 06/24/2025 11:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2025 11:05:23 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2025 11:05:10 AM
- Amarin Reports First Quarter 2025 Financial Results • GlobeNewswire Inc. • 05/07/2025 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2025 08:20:08 PM
- Amarin Regains Compliance with Nasdaq Minimum Bid Price Requirement • GlobeNewswire Inc. • 04/29/2025 08:15:00 PM
- Amarin to Report First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025 • GlobeNewswire Inc. • 04/28/2025 08:15:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/23/2025 01:00:12 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/23/2025 01:00:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/23/2025 01:00:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/23/2025 01:00:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/23/2025 01:00:06 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/23/2025 01:00:05 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/23/2025 01:00:05 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/23/2025 01:00:03 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 04/11/2025 10:00:07 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2025 09:01:21 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2025 11:30:16 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/09/2025 11:35:08 AM
- Amarin Confirms Effective Date for 1-For-20 ADS Ratio Change • GlobeNewswire Inc. • 04/09/2025 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/09/2025 11:25:08 AM
- Form PRER14A - Preliminary Proxy Soliciting materials • Edgar (US Regulatory) • 04/07/2025 11:50:42 AM
Branded Legacy Inc. Announces Leadership Transition and Pending Merger with Innovative Addiction Therapeutics Company Projecting $40 Million in First-Year Revenue • BLEG • Jul 14, 2025 1:23 PM
VAYK Project 100% Revenue Growth Before Half Year Report • VAYK • Jul 14, 2025 8:58 AM
Glidelogic Corp. Announces Release of First AI-Generated Novel "The Thirteenth Proposal" • GDLG • Jul 11, 2025 12:20 PM
Fifty1 AI Labs' REVIVE Clinical Trial Redefines Long COVID Treatment, Pioneering AI-Driven Therapies and Propelling Fifty 1 Labs, Inc. Toward $50M Valuation and Global Biotech Leadership • FITY • Jul 10, 2025 8:30 AM
Aspire Biopharma Holdings, Inc., Announces Positive Consumer Feedback from Company Sampling of BUZZ BOMB™, its New Sublingual Pre-Workout Supplement • ASBP • Jul 9, 2025 9:15 AM
Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers • IBRX • Jul 9, 2025 9:00 AM